HC Wainwright Estimates Cibus’ Q3 Earnings (NASDAQ:CBUS)

Cibus, Inc. (NASDAQ:CBUS) – Equities researchers at HC Wainwright dropped their Q3 2026 EPS estimates for Cibus in a note issued to investors on Friday, August 14th. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings per share of ($0.27) for the quarter, down from their previous estimate of ($0.24). The consensus estimate for Cibus’ current full-year earnings is ($1.05) per share. HC Wainwright also issued estimates for Cibus’ Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.13) EPS, FY2027 earnings at ($1.07) EPS and FY2028 earnings at ($0.50) EPS.

Cibus (NASDAQ:CBUS) last posted its earnings results on Thursday, August 13th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.10). The business had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.70 million. Cibus had a negative return on equity of 287.03% and a negative net margin of 2,258.89%.

Several other equities analysts also recently commented on the stock. Wall Street Zen raised shares of Cibus from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Weiss Ratings cut Cibus from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Cibus presently has a consensus rating of “Hold” and an average price target of $9.00.

Cibus Trading Down 5.6%

Cibus stock opened at $1.67 on Tuesday. Cibus has a 1-year low of $1.09 and a 1-year high of $4.19. The firm’s fifty day simple moving average is $1.66 and its 200-day simple moving average is $1.97. The company has a market capitalization of $127.47 million, a P/E ratio of -1.01 and a beta of 1.61.

Institutional Trading of Cibus

A number of institutional investors and hedge funds have recently modified their holdings of the company. Weiss Asset Management LP bought a new stake in shares of Cibus during the 1st quarter worth $1,758,000. Prescott Group Capital Management L.L.C. bought a new position in Cibus in the 4th quarter worth $345,000. Jane Street Group LLC bought a new position in Cibus in the 2nd quarter worth $207,000. Certior Financial Group LLC lifted its position in Cibus by 46.7% during the 4th quarter. Certior Financial Group LLC now owns 271,164 shares of the company’s stock worth $472,000 after acquiring an additional 86,378 shares during the last quarter. Finally, Corient Private Wealth LLC acquired a new position in Cibus during the 4th quarter worth $145,000. 33.81% of the stock is currently owned by institutional investors and hedge funds.

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.